{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:36:11Z","timestamp":1792067771102,"version":"4.4.0"},"reference-count":49,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2023,5,20]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells and is synergistic with azacitidine, which increases expression of eat-me signals. We report final phase Ib data in patients with untreated higher-risk myelodysplastic syndromes (MDS) treated with magrolimab and azacitidine (ClinicalTrials.gov identifier: NCT03248479 ). <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> Patients with previously untreated Revised International Prognostic Scoring System intermediate-\/high-\/very high-risk MDS received magrolimab intravenously as a priming dose (1 mg\/kg) followed by ramp-up to a 30 mg\/kg once\u2010weekly or once\u2010every-2-week maintenance dose. Azacitidine 75 mg\/m<jats:sup>2<\/jats:sup> was administered intravenously\/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety\/tolerability and complete remission (CR) rate. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Ninety-five patients were treated. Revised International Prognostic Scoring System risk was intermediate\/high\/very high in 27%, 52%, and 21%, respectively. Fifty-nine (62%) had poor-risk cytogenetics and 25 (26%) had TP53 mutation. The most common treatment-emergent adverse effects included constipation (68%), thrombocytopenia (55%), and anemia (52%). Median hemoglobin change from baseline to first postdose assessment was \u22120.7 g\/dL (range, \u22123.1 to +2.4). CR rate and overall response rate were 33% and 75%, respectively. Median time to response, duration of CR, duration of overall response, and progression-free survival were 1.9, 11.1, 9.8, and 11.6 months, respectively. Median overall survival (OS) was not reached with 17.1-month follow-up. In TP53-mutant patients, 40% achieved CR with median OS of 16.3 months. Thirty-four patients (36%) had allogeneic stem-cell transplant with 77% 2-year OS. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Magrolimab + azacitidine was well tolerated with promising efficacy in patients with untreated higher-risk MDS, including those with TP53 mutations. A phase III trial of magrolimab\/placebo + azacitidine is ongoing (ClinicalTrials.gov identifier: NCT04313881 [ENHANCE]). <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.22.01794","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T21:00:18Z","timestamp":1678309218000},"page":"2815-2826","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":190,"title":["Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study"],"prefix":"10.1200","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct03248479","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David A.","family":"Sallman","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Asch","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center-University of Oklahoma Health Sciences Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0968","authenticated-orcid":false,"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Jurcic","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence J.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-290X","authenticated-orcid":false,"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-4860","authenticated-orcid":false,"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kambhampati","sequence":"additional","affiliation":[{"name":"Sarah Cannon Cancer Institute, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7656-5249","authenticated-orcid":false,"given":"Tiffany N.","family":"Tanaka","sequence":"additional","affiliation":[{"name":"University of California San Diego Moores Cancer Center, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1514","authenticated-orcid":false,"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[{"name":"University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-1814","authenticated-orcid":false,"given":"Deepa","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"University of California Irvine, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Tan","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Chao","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"O'Hear","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridharan","family":"Ramsingh","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu","family":"Lal","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3931-0914","authenticated-orcid":false,"given":"Paresh","family":"Vyas","sequence":"additional","affiliation":[{"name":"MRC Molecular Haematology Unit, Oxford BRC, Department of Hematology, Weatherall Institute of Molecular Medicine, University of Oxford and Oxford University Hospitals NHS Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.07.012"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.771614"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03380"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106555"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4346"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.9245"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30533"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01125-4"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14305"},{"key":"b18","volume-title":"Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial","author":"Takada","year":"2021"},{"key":"b19","volume-title":"Aprea Therapeutics Announces Results of Primary Endpoint From Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)","author":"Aprea Therapeutics","year":"2020"},{"key":"b20","volume-title":"Onconova Therapeutics Announces Topline Results From the Pivotal Phase 3 INSPIRE Trial","author":"Onconova Therapeutics","year":"2020"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005487"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.01.010"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5473.2051"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222861110"},{"key":"b26","doi-asserted-by":"crossref","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","volume":"10","author":"Liu J","year":"2015","journal-title":"PLoS One"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-120170"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147479"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01380"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6394"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119424"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17689"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045"},{"key":"b37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305569110"},{"key":"b38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02018"},{"key":"b39","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070"},{"key":"b40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01348.x"},{"key":"b41","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24930"},{"key":"b42","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001101"},{"key":"b43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7290"},{"key":"b44","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003508"},{"key":"b45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23882"},{"key":"b46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.304"},{"key":"b47","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn349"},{"key":"b48","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.88"},{"key":"b49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.01.009"},{"key":"b50","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.03.029"},{"key":"b51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01367-w"},{"key":"b52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153638"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.22.01794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T22:01:24Z","timestamp":1684360884000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.22.01794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":49,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,5,20]]}},"alternative-id":["10.1200\/JCO.22.01794"],"URL":"https:\/\/doi.org\/10.1200\/jco.22.01794","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,20]]},"assertion":[{"value":"2022-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}